论文部分内容阅读
目的:特发性肺纤维化相关性肺高压预后不佳,治疗乏术。本研究对ROCK拮抗剂法舒地尔在其治疗中发挥的作用进行了临床研究。方法:对40名入选的特发性肺纤维化相关性肺高压患者分为两组,分别接受普通抗纤维化治疗及普通抗纤维化治疗基础上加用法舒地尔治疗,2周后检测肺动脉压力、6分钟步行距离的改善情况及患者血气分析结果。结果:与对照组相比,法舒地尔组肺动脉压力降低,同时6分钟步行距离提高,其差异均具有统计学意义。结论:法舒地尔可降低肺动脉压力,提高运动耐量,改善氧和的作用,因此在特发性肺纤维化相关性肺高压中具有良好的治疗作用。
Objectives: Idiopathic pulmonary fibrosis-related pulmonary hypertension has a poor prognosis and is refractory to treatment. In this study, ROCK antagonist Fasudil in the treatment of its role in a clinical study. Methods: Forty selected patients with idiopathic pulmonary fibrosis-related pulmonary hypertension were divided into two groups, treated with fasudil after general antifibrosis treatment and general antifibrosis treatment respectively. Pulmonary artery Pressure, 6-minute walking distance improvement and patient blood gas analysis results. RESULTS: Compared with the control group, fasudil decreased pulmonary artery pressure and increased walking distance at 6 minutes. The difference was statistically significant. Conclusion: fasudil can reduce pulmonary arterial pressure, increase exercise tolerance and improve the role of oxygen and therefore has a good therapeutic effect in idiopathic pulmonary fibrosis-associated pulmonary hypertension.